Welcome to our dedicated page for Portage Biotech SEC filings (Ticker: PRTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PRTG filings document a foreign-private-issuer record that later appears under AlphaTON Capital Corp and Alpha Compute Corp, with disclosures covering corporate-status changes, Nasdaq listing matters, capital raising and governance. Form 6-K reports describe amendments to the issuer's British Virgin Islands memorandum and articles, a corporate name change, registration-statement incorporation and related trading-symbol changes.
The filing record also includes Nasdaq minimum-bid-price correspondence, board composition changes and an at-the-market ordinary share offering conducted under a Form F-3 shelf registration statement. These filings frame the issuer's capital structure, charter documents, exchange compliance and public-company reporting status.
AlphaTON Capital Corp established an at-the-market share offering program allowing it to sell up to $400,000,000 of its ordinary shares through H.C. Wainwright & Co. as sales agent or principal. Sales will be made under an effective Form F-3 shelf and a new prospectus supplement, with commissions of up to 3.0% of gross proceeds.
The company plans to use any net proceeds to fund capital spending for development, training and operation of its Cocoon AI platform, including servers, GPUs and related infrastructure, to pursue complementary acquisitions or investments, and for working capital and other general corporate purposes.
AlphaTON Capital Corp established an at-the-market share offering program allowing it to sell up to $400,000,000 of its ordinary shares through H.C. Wainwright & Co. as sales agent or principal. Sales will be made under an effective Form F-3 shelf and a new prospectus supplement, with commissions of up to 3.0% of gross proceeds.
The company plans to use any net proceeds to fund capital spending for development, training and operation of its Cocoon AI platform, including servers, GPUs and related infrastructure, to pursue complementary acquisitions or investments, and for working capital and other general corporate purposes.
AlphaTON Capital Corp is launching an at-the-market equity program to sell up to $400,000,000 of ordinary shares through H.C. Wainwright as sales agent or principal. Shares may be sold from time to time on Nasdaq under the symbol ATON or through other permitted methods at prevailing market prices.
The company plans to use net proceeds mainly to fund capital expenditures for Cocoon AI, including servers, GPUs and related infrastructure, and to pursue strategic acquisitions or investments aligned with the Telegram and TON ecosystem, with any remainder for working capital and general corporate purposes.
As context, AlphaTON reports 23,434,588 ordinary shares outstanding as of February 13, 2026, so issuing a large portion of the program would significantly increase the share count and dilute existing holders. Wainwright will receive up to a 3.0% sales commission on gross proceeds.
AlphaTON Capital Corp is launching an at-the-market equity program to sell up to $400,000,000 of ordinary shares through H.C. Wainwright as sales agent or principal. Shares may be sold from time to time on Nasdaq under the symbol ATON or through other permitted methods at prevailing market prices.
The company plans to use net proceeds mainly to fund capital expenditures for Cocoon AI, including servers, GPUs and related infrastructure, and to pursue strategic acquisitions or investments aligned with the Telegram and TON ecosystem, with any remainder for working capital and general corporate purposes.
As context, AlphaTON reports 23,434,588 ordinary shares outstanding as of February 13, 2026, so issuing a large portion of the program would significantly increase the share count and dilute existing holders. Wainwright will receive up to a 3.0% sales commission on gross proceeds.
AlphaTON Capital Corp reported changes to its board of directors. On February 5, 2026, Steven Mintz informed the company that he would resign from the board, effective February 6, 2026.
On February 6, 2026, F. Daniel Siciliano joined the board following a unanimous vote in favor by the existing directors, providing continuity in board governance following the resignation.
AlphaTON Capital Corp reported changes to its board of directors. On February 5, 2026, Steven Mintz informed the company that he would resign from the board, effective February 6, 2026.
On February 6, 2026, F. Daniel Siciliano joined the board following a unanimous vote in favor by the existing directors, providing continuity in board governance following the resignation.
AlphaTON Capital Corp received an amended ownership report showing that Orca Capital, a Germany-based investor, beneficially owns 640,000 Ordinary Shares, equal to 4.5% of the class. Orca has sole power to vote and dispose of all these shares.
The percentage is calculated using 14,314,588 Ordinary Shares outstanding, reflecting AlphaTON’s registered offering described in a prospectus filed on January 15, 2026. Orca filed on a passive basis, certifying the shares were not acquired to change or influence control of the company.
AlphaTON Capital Corp received an amended ownership report showing that Orca Capital, a Germany-based investor, beneficially owns 640,000 Ordinary Shares, equal to 4.5% of the class. Orca has sole power to vote and dispose of all these shares.
The percentage is calculated using 14,314,588 Ordinary Shares outstanding, reflecting AlphaTON’s registered offering described in a prospectus filed on January 15, 2026. Orca filed on a passive basis, certifying the shares were not acquired to change or influence control of the company.
AlphaTON Capital Corp reported that it has raised net $44 million in capital and is now generating revenue from its confidential compute AI infrastructure connected to Telegram’s Cocoon network. This marks a shift from being mainly a digital asset holder to operating revenue-producing AI infrastructure.
The company closed a $15 million registered direct offering at $1.00 per share, with most proceeds directed to GPU-based AI infrastructure for Cocoon AI and working capital. It initiated a $46 million investment for 576 NVIDIA B300 chips, scheduled for delivery in March 2026, which is projected to deliver a 27% IRR, 282% ROI and a Net Present Value of $11 million.
AlphaTON exited SEC baby-shelf limits and obtained effectiveness for a $420.69 million shelf registration, enhancing financing flexibility. It has deployed B200 and H200 GPUs, signed a five-year, 2.2 MW colocation deal in Sweden powered by renewable energy, and launched new products and partnerships, including the Cocoon AI network, Midnight Foundation agreement and AlphaTON Claude Connector, all aimed at building recurring, privacy-preserving AI and blockchain-based revenue streams.
AlphaTON Capital Corp filed an amended Form 6-K to add unaudited condensed interim financial statements and XBRL data for the three and six months ended September 30, 2025. The company has pivoted from a legacy immuno-oncology focus to a technology and digital-asset strategy built around the Telegram ecosystem and TON blockchain, including staking, DeFi activities and Telegram-based applications.
For the six months ended September 30, 2025, AlphaTON reported a net loss of about $11.1 million, with basic and diluted loss per share of $5.13. As of September 30, 2025, cash and cash equivalents were $0.2 million against current liabilities of $21.5 million, while total assets were $30.6 million, including stablecoins of $3.1 million, digital assets of $1.8 million, and digital asset and stablecoin receivables of $23.9 million.
In September 2025 the company completed a private placement of ordinary shares and pre-funded warrants with aggregate consideration of approximately $36.2 million in cash, digital assets and stablecoins, and recognized a put right liability of $17.9 million related to contingent repurchase and treasury arrangements. The financial statements include a going concern note stating that recurring losses, limited cash and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern within one year of the statements’ issuance date.
AlphaTON Capital Corp filed an amended Form 6-K to add unaudited condensed interim financial statements and XBRL data for the three and six months ended September 30, 2025. The company has pivoted from a legacy immuno-oncology focus to a technology and digital-asset strategy built around the Telegram ecosystem and TON blockchain, including staking, DeFi activities and Telegram-based applications.
For the six months ended September 30, 2025, AlphaTON reported a net loss of about $11.1 million, with basic and diluted loss per share of $5.13. As of September 30, 2025, cash and cash equivalents were $0.2 million against current liabilities of $21.5 million, while total assets were $30.6 million, including stablecoins of $3.1 million, digital assets of $1.8 million, and digital asset and stablecoin receivables of $23.9 million.
In September 2025 the company completed a private placement of ordinary shares and pre-funded warrants with aggregate consideration of approximately $36.2 million in cash, digital assets and stablecoins, and recognized a put right liability of $17.9 million related to contingent repurchase and treasury arrangements. The financial statements include a going concern note stating that recurring losses, limited cash and reliance on external financing raise substantial doubt about the company’s ability to continue as a going concern within one year of the statements’ issuance date.
AlphaTON Capital Corp outlines key terms of a planned financing and related agreements to support a TON digital asset treasury strategy for the Telegram ecosystem. Under a treasury management agreement, the company will appoint DWF MaaS Limited to manage an initial $20 million, with a further $55 million to be transferred within three months, and DWF’s revenue share and profit share increasing with funding and asset balances. DWF will also receive equity linked to up to 160,000 ordinary shares, vesting over three years, and may convert ordinary shares acquired in the offering into TON within twelve months.
The company expects gross proceeds of about $36.2 million from the financing, which it currently expects to close during the week of September 22, 2025, and certain TON contributors will be subject to staged lock-up releases over up to ten months. A revised master loan arrangement with BitGo Prime, LLC permits drawdowns of up to $35,000,000 at a 14.75% annual interest rate plus fees, secured by TON collateral at up to 200% of the drawn amount, with a six-month repayment term and specified margin and liquidation thresholds.
Alphaton Capital Corp. entered into an at-the-market offering agreement with Chardan Capital Markets, LLC, allowing it to sell ordinary shares from time to time with an aggregate offering price of up to $2,841,450 under its effective Form F-3 shelf registration.
Chardan will act as sales agent and/or principal and receive a 3.0% cash commission on the gross sales price of any shares sold, plus expense reimbursement. The program will end when all $2,841,450 of shares are sold under the prospectus supplement or the agreement is otherwise terminated.
Portage Biotech Inc. files a prospectus supplement describing an offering of securities and related risks, governance and tax considerations. The supplement discloses the potential issuance of approximately 3,746,443 ordinary shares and 2,921,808 ordinary shares upon settlement of pre-funded warrants from a private placement, plus multiple tranches of shares reserved for executives, employees, contractors, service providers and equity incentives (including specific amounts such as 478,851, 17,452, 244,221, 191,980, and 47,828 ordinary shares under various agreements).
The supplement highlights material risks: exposure to a recently developed digital asset (TON) with potential volatility and custody/insurance shortcomings; debt-related risks including default, acceleration and loss of collateral; limited liquidity and trading risks (including penny-stock designation); and data-protection obligations and penalties under the British Virgin Islands data protection regime. The document also lists incorporated SEC reports and the Form 8-A description of ordinary shares as sources of further detail.
Portage Biotech Inc. (PRTG) filed a Form 6‑K disclosing a set of material agreements and company documents made available as exhibits. The filing lists an At‑The‑Market Offering Agreement with Chardan Capital Market, LLC (July 30, 2025), a Master Loan Agreement with BitGo Prime, LLC (August 28, 2025), multiple securities purchase and registration agreements, forms of pre‑funded warrants and side letters, and several independent contractor and amendment agreements dated in August 2025. The filing also includes a press release and investor presentation dated September 3, 2025.
These exhibits indicate preparatory financing activity (equity and cryptocurrency securities), new counterparty credit arrangements, and expanded external contractor relationships. The combination of an ATM facility, registration rights and debt with a crypto custodian suggests the company is arranging capital and operational partnerships to support near‑term funding and execution; however, the filing provides exhibit descriptions only and does not disclose monetary sizes, pricing, or full contractual terms within this document.